G
G. Del Conte
Researcher at Vita-Salute San Raffaele University
Publications - 20
Citations - 423
G. Del Conte is an academic researcher from Vita-Salute San Raffaele University. The author has contributed to research in topics: Carboplatin & Pemetrexed. The author has an hindex of 6, co-authored 20 publications receiving 381 citations.
Papers
More filters
Journal ArticleDOI
Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials
Giovanni Luca Ceresoli,B. Castagneto,Paolo Andrea Zucali,Adolfo Favaretto,Manlio Mencoboni,Francesco Grossi,Diego Cortinovis,G. Del Conte,Anna Ceribelli,Alessandra Bearz,S. Salamina,F. De Vincenzo,Federico Cappuzzo,Maurizio Marangolo,Valter Torri,Armando Santoro +15 more
TL;DR: The PC regimen is effective and well tolerated in selected elderly patients with MPM, and there was no significant difference in outcome or toxicity between age groups.
Journal ArticleDOI
Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours
G. Del Conte,Cristiana Sessa,R. von Moos,Lucia Viganò,Tiziana Digena,Alberta Locatelli,Elisa Gallerani,Angelica Fasolo,A Tessari,Richard Cathomas,Luca Gianni +10 more
TL;DR: Continuous/intermittent olaparib (up to 400’mg bid) combined with PLD (40 mg m−2) was generally tolerated and showed evidence of antitumour activity in ovarian cancer.
Journal ArticleDOI
A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer
Stan B. Kaye,Christopher J. Poole,A. Dańska-Bidzińska,Luca Gianni,G. Del Conte,Vera Gorbunova,E. Novikova,A. Strauss,M. Moczko,V. McNally,Graham Ross,Ignace Vergote +11 more
TL;DR: The addition of pertuzumab to carboplatin-based chemotherapy did not substantially prolong PFS in unselected patients with platinum-sensitive, recurrent advanced ovarian cancer.
Journal ArticleDOI
A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors
Juneko E. Grilley-Olson,Philippe L. Bedard,Angelica Fasolo,Cornfeld Mark J,Cornfeld Mark J,Cornfeld Mark J,Leanne Cartee,Leanne Cartee,Albiruni Ryan Abdul Razak,Lee-Anne Stayner,Yuehui Wu,Yuehui Wu,R. Greenwood,R. Greenwood,R. Greenwood,Rajeshwar Singh,Rajeshwar Singh,Carrie B. Lee,Johanna C. Bendell,H. A. Burris,G. Del Conte,Cristiana Sessa,J. R. Infante +22 more
TL;DR: GSK458 plus trametinib is poorly tolerated, due to skin and GI-related toxicities, which may be due to overlapping toxicities precluding sufficient dose exposure.
Journal ArticleDOI
Results from a phase 1/2 study of volociximab in combination with liposomal doxorubicin in relapsed advanced epithelial ovarian and primary peritoneal carcinoma
Angelo Delmonte,G. Del Conte,Cristiana Sessa,Antonella Perotti,Angelica Fasolo,E. Williams,K. Smith,E. DallO,Nicola Colombo,Luca Gianni +9 more
TL;DR: Preclinical studies demonstrate that the chimeric α5β1 integrin antibody volociximab inhibits tumor angiogenesis by blocking binding of activated vascular endothelial cells to fibroblasts.